BioCentury
ARTICLE | Translation in Brief

Philogen immunocytokine for glioma; plus Nordic's radiotherapy, Beth Israel Deaconness, Molecular Partners and Alpine

BioCentury’s roundup of translational news

October 9, 2020 10:36 PM UTC

Philogen immunocytokine for brain cancer
University of Zurich and Swiss Federal Institute of Technology Zurich (ETHZ) scientists reported data from the first three patients with grade III/IV glioblastoma in a Phase I/II trial of  Philogen S.p.A.’s Fibromun (L19-TNF) showing intratumoral necrosis within 24 hours of the second infusion. In a Science Translational Medicine paper, they also demonstrated in mice with brain tumors that a mouse version of Fibromun and another immunocytokine reduced tumor size and mortality survival, boosted numbers of tumor-infiltrating lymphocytes and raised levels of proinflammatory cytokines in the tumor microenvironment.

Nordic radiotherapy reduces rituximab resistance
Nordic Nanovector ASA (OSE:NANO) described in The Journal of Nuclear Medicine the use of betalutin (177Lu-satetraxetan-lilotomab) to reverse rituximab resistance in a xenograft mouse model of non-Hodgkin's lymphoma . The radioimmunotherapy plus rituximab inhibited tumor growth and increased survival compared with either treatment alone. The combination therapy is in Phase I testing to treat lymphoma...